A burst of new partnerships to fuel respiratory research
The number of new Covid-19 cases in China is starting to drop off, but the outbreak has resulted in some notable health tech collaborations that are just getting started. Tech giant Tencent announced it’s joining the fray by setting up a data and artificial intelligence lab with prominent respiratory disease expert Zhong Nanshan and his team of respiratory specialists, the South China Morning Post reported.
“The priority of the joint lab is to combat the coronavirus. The longer-term goal is to tackle screening and provide early warning of epidemics, respiratory diseases and chest diseases through the use of big data and artificial intelligence,” Tencent said on its official WeChat account, China’s version of Twitter.
The unveiling of Zhong’s partnership with Tencent comes after Alibaba Group’s Jack Ma pledged $1.4 million to help the scientist develop new drugs to treat the novel coronavirus through his Jack Ma Foundation, according to Xinhua. Ma’s cloud computing subsidiary, Alibaba Cloud, will also support the research by providing AI computing services for drug development, viral gene-sequencing, and protein screening.
Zhong is the director of the Guangzhou Institute of Respiratory Disease. Harvard Medical School last month announced a five-year, $115 million research collaboration deal with the institute.
“The priority of the joint lab is to combat the coronavirus. The longer-term goal is to tackle screening and provide early warning of epidemics, respiratory diseases and chest diseases through the use of big data and artificial intelligence,” Tencent said on its official WeChat account, China’s version of Twitter.
The unveiling of Zhong’s partnership with Tencent comes after Alibaba Group’s Jack Ma pledged $1.4 million to help the scientist develop new drugs to treat the novel coronavirus through his Jack Ma Foundation, according to Xinhua. Ma’s cloud computing subsidiary, Alibaba Cloud, will also support the research by providing AI computing services for drug development, viral gene-sequencing, and protein screening.
Zhong is the director of the Guangzhou Institute of Respiratory Disease. Harvard Medical School last month announced a five-year, $115 million research collaboration deal with the institute.
.png)
No hay comentarios:
Publicar un comentario